24/7 Customer Support

Respiratory Syncytial Virus Market - Industry Dynamics, Market Size, and Opportunity Forecast to 2032

Global Respiratory Syncytial Virus Market, By Drug Type (Synagis, Virazole, Palivizumab, Riba Tab and Others), By Dosage Form (Oral, Injectable, Inhaler and Others), By Treatment Type (Immune Prophylaxis, Supportive Care and Antiviral Medications), By Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies and Clinics), By Region(North America, Europe, Asia Pacific, South America, Middle East & Africa; Region—Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2024–2032

  • Published Date: 09-Feb-2024  |   Format: pdfpowerpointexcel  |  Report ID: AA0821085
    Delivery: 2 to 4 Hours
INFOGRAPHIC:
Respiratory Syncytial Virus Market

View Full Infographic

REPORT SCOPE

Report AttributeDetails
Market Size Value in 2023US$ 2,331.3 Mn
Expected Revenue in 2032US$ 8,137.2 Mn
Historic Data2019-2022
Base Year2023
Forecast Period2024-2031
UnitValue (USD Mn)
CAGR14.9% 
Segments coveredBy Drug Type, By Dosage Form, By Treatment Type, By Distribution Channel, By Region
Key Companies                                                                                                       AbbVie, Inc., AstraZeneca PLC, Atea Pharmaceuticals, Bausch Health Companies Inc., Celltrion Inc., Enanta Pharmaceuticals, Inc, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson's, mAbxience, Medivir AB, Merck Co., Inc., Pfizer Inc., ReViral Ltd., Sanofi, Teva Pharmaceutical Industries Ltd., Other Prominent Players
Customization ScopeGet your customized report as per your preference. Ask for customization

LOOKING FOR COMPREHENSIVE MARKET KNOWLEDGE? ENGAGE OUR EXPERT SPECIALISTS.

SPEAK TO AN ANALYST